Gene
TPMT
TPMT is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (3), Actionable biomarkers (9), Trial mentions (54), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention TPMT. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 5 of 8,738 | 0.06% | not measured | |
| 2025 | 3 of 8,875 | 0.03% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 3 of 11,460 | 0.03% |
| 2022 | 2 of 8,285 | 0.02% | 7 of 13,598 | 0.05% |
| 2021 | 3 of 8,692 | 0.03% | 7 of 15,045 | 0.05% |
| 2020 | 1 of 7,640 | 0.01% | 14 of 14,459 | 0.10% |
| 2019 | 4 of 7,300 | 0.05% | 9 of 12,159 | 0.07% |
| 2018 | 0 of 6,927 | 0.00% | 6 of 11,854 | 0.05% |
| 2017 | 5 of 6,558 | 0.08% | 10 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (3)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Illumina | Unclassified | Clinical validation | 1 | June 01, 2020 |
| Sanquin Research | Diagnostic provider | Clinical validation | 1 | June 01, 2020 |
| Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University | Not a company | Clinical validation | 1 | February 28, 2018 |
Actionable biomarkers (9)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| TPMT biallelic inactivation | Thioguanine | other | No disease recorded | Cancer Genome Interpreter |
| TPMT splice acceptor variant | MERCAPTOPURINE | other | No disease recorded | Cancer Genome Interpreter |
| TPMT splice acceptor variant | Thioguanine | other | No disease recorded | Cancer Genome Interpreter |
| TPMT splice acceptor variant | CISPLATIN | other | No disease recorded | Cancer Genome Interpreter |
| TPMT biallelic inactivation | MERCAPTOPURINE | other | No disease recorded | Cancer Genome Interpreter |
Showing 5 of 9 actionable-biomarker assertions.
Trial mentions (54)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01556386 | Trial biospecimen (AACT) |
| NCT01697020 | Trial eligibility (AACT) |
| NCT00741338 | Trial eligibility (AACT) |
| NCT04761952 | Trial eligibility (AACT) |
| NCT05349006 | Trial eligibility (AACT) |
Showing 5 of 54 trial mentions.
Target-disease associations (54)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Autoimmune Hepatitis | endocrine system disease | Literature (Europe PMC) |
| Behcet's syndrome | cardiovascular disease | Literature (Europe PMC) |
| Crohn's disease | gastrointestinal disease | Literature (Europe PMC) |
| Decreased total leukocyte count | phenotype | Literature (Europe PMC) |
Showing 5 of 54 associations.
Vendor sourcing (214)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Aalborg University Hospital | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Confirmed histomorphological or cytomorphological diagnosis of NHL or ALL. * Meets just one of the following: 1. Patient with NHL treated after the E... | View trial NCT02141100 |
| Aalborg University Hospital | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Willingness to comply with all trial procedures and being available for the duration of the trial. * Clinically and histologically verified ulcerative c... | View trial NCT03101800 |
| Aalborg University Hospital | Trial collaborator | Mentioned in trial textTrial free-text mention | TPMT | View trial NCT03101800 |
| Aalborg University Hospital | Trial collaborator | Mentioned in trial textTrial free-text mention | TPMT | View trial NCT02141100 |
| Aarhus University Hospital | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Willingness to comply with all trial procedures and being available for the duration of the trial. * Clinically and histologically verified ulcerative c... | View trial NCT03101800 |
Showing 5 of 214 sourcing records.
Trial-cited literature (123)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS. | Clinical pharmacology and therapeutics | 2026 | 2 |
| Estimating the Frequency of False-Negative Pharmacogenetic Test Results by Self-Reported Ancestry. | Clinical pharmacology and therapeutics | 2025 | 1 |
| Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. | Journal of neurology | 2024 | 208 |
| Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial. | Clinical pharmacology and therapeutics | 2024 | 5 |
| Experimental pharmacology in precision medicine. | Pharmacology research & perspectives | 2023 | 5 |
Showing 5 of 123 papers.
Protein variant mentions (5)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A154T | 9 | 2009 to 2020 | PMID 31446180, PMID 32629971, PMID 32939381 |
| p.A80P | 8 | 2009 to 2020 | PMID 31446180, PMID 32326111, PMID 32629971 |
| p.G460W | 1 | 2016 | PMID 26752539 |
| p.R215H | 1 | 2017 | PMID 27564568 |
| p.Y240C | 13 | 2009 to 2020 | PMID 31446180, PMID 32326111, PMID 32481505 |
Literature-extracted relations (65)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| MERCAPTOPURINE | Chemical | associate |
Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial. | 2024 |
| Epoprostenol | Chemical | associate |
Fetal pharmacogenomics: A promising addition to complex neonatal care. | 2022 |
| CISPLATIN | Chemical | associate |
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. | 2020 |
| CISPLATIN | Chemical | associate |
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. | 2020 |
| MERCAPTOPURINE | Chemical | associate |
Star Allele-Based Haplotyping versus Gene-Wise Variant Burden Scoring for Predicting 6-Mercaptopurine Intolerance in Pediatric Acute Lymphoblastic Leukemia Patients. | 2019 |
Showing 5 of 65 relation assertions.
Organizations publishing (183)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Novant Health | Hospital | 20 | 1999 to 2026 |
| Mayo Clinic | Hospital | 5 | 2011 to 2019 |
| University of Groningen | Academic | 5 | 2005 to 2022 |
| University of Pennsylvania | Academic | 5 | 2017 to 2023 |
| Aarhus University Hospital | Hospital | 4 | 2017 to 2020 |
Showing 5 of 183 organizations.
Where TPMT appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
53 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.